

China's WuXi Biologics launches WuXia RidGS for non-antibiotic cell line development

29 October 2024 | News

WuXia RidGS ensures cell line stability for mAbs, as well as for various other therapeutic modalities

China-based WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the launch of WuXia RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform.

The platform, specialised in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the endogenous GS gene in CHO cells.

Based on the WuXia platform, WuXia RidGS not only retains the robust cell growth, metabolism, and expression profile characteristic of WuXia, but also boasts an average clonal expression level exceeding 6 g/L for monoclonal antibodies (mAbs).

WuXia RidGS ensures cell line stability for mAbs, as well as for various other therapeutic modalities, including bispecific antibodies, Fc-fusion proteins, and recombinant proteins. The quality of protein products expressed by the platform showcases favourable glycosylation patterns while maintaining an exceptional purity profile.

In addition, without the need for antibiotics, WuXia RidGS host and production cells consistently maintain stable productivity and uniform product quality throughout extensive, long-term cell line stability studies.

WuXia is a proven, high-yielding (up to about 11 g/L) mammalian cell line platform developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia platform has generated over 900 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing.